Source: Annual Congress 2006 - Screening, diagnosis, staging, prognosis, biological features
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Naoki, H. Kunikane, H. Okamoto, N. Hida, Y. Narita, I. Nakachi, I. Kawada, H. Watanabe, H. Yasuda, K. Soejima, A. Ishizaka, K. Watanabe (Yokohama, Tokyo, Japan). The usefulness of Cyfra 21-1 as a disease marker in malignant pleural mesothelioma (MPM). Eur Respir J 2006; 28: Suppl. 50, 581

Member's Comments

No comment yet.

Related content which might interest you: Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 Diagnostic utility of pleural CEA and CYFRA 21-1 for malignant pleural effusions Source: Eur Respir J 2003; 22: Suppl. 45, 60s Year: 2003 Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002 Prognostic significance of serum and pleural mesothelin in malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Diagnostic utility of CYFRA 21-1 and carcinoembryonic antigen as a tumour markers in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Utility of serum soluble mesothelin as a follow-up marker in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Clinical evaluation of NSE, CYFRA 21-1, CEA and MCA at patients (pts.) with metastatic pleural effusion (PE) Source: Eur Respir J 2005; 26: Suppl. 49, 448s Year: 2005 Tumour marker (TM) CA 19-9 in pleural fluid at patients with malignant and paramalignant pleural effusion (PE) Source: Eur Respir J 2001; 18: Suppl. 33, 387s Year: 2001 Comparative evaluation of CA-125, CA 19-9, CA 15-3 and CEA in exudative benign and malignant pleural effusion Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010 The diagnostic value of mucinous carcinoma - associated antigen (MCA) testin differentiation of malignant from benign pleural effusion (PE) Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 The presence of human mammaglobin transcripts in the pleural effusion is not predictive of survival in patients with malignant mesothelioma Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008 Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004 Tumor markers (TM) CEA, MCA and CA 19-9 in pleural effusion (PE) at malignant mezothelioma and methastatic tumour of pleura Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 CEA, Cyfra 21.1 and NSE levels in malignant and benign pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Malignant pleural mesothelioma (MPM) – 5 years of experience Source: Eur Respir J 2006; 28: Suppl. 50, 91s Year: 2006 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005 Clinical and morphological prognostic factors in patients with malignant pleura mesothelioma (MPM) Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010